A

AbbVie

Global biopharmaceutical company developing medicines

Senior Analyst - National Data Operations

Full-TimePosted on 10/21/2026
$84.5k - $162k/yr+ Short-term incentive program
Mid
Master's, MBA, Bachelor of Arts (BA), Bachelor of Science (BS)
Mettawa, IL, USA
Hybrid
Data & AnalyticsData Management

About the job

Requirements
  • A BA or BS degree is required.
  • A bachelor's degree plus at least 3 years of related analytics work experience, or a master's degree plus at least 2 years of related work experience in business, system, commercial analytics, or IT/systems is required.
  • Strong working knowledge and experience with artificial intelligence, SQL, Power BI, and Excel are required; expert-level Excel data analysis and pivot table skills are essential.
  • Experience performing user acceptance testing and reconciling data across source files, data repositories, development and production environments, and executive reporting outputs is required, including documenting evidence and driving discrepancy resolution with technical and business partners.
  • A demonstrated record of effectively managing data-related processes in a matrixed internal environment and with vendor partners is required, reflecting attention to detail, proactive issue management, and cross-functional communication.
  • Strong analytical reasoning, intellectual curiosity, business acumen, and creativity in problem-solving are required.
  • The ability to synthesize substantial amounts of information into concise, understandable communications is required.
  • The ability to build strong relationships with peers and cross-functional partners is required.
  • The candidate must be open to suggestions and experimentation for improvement, embrace others' ideas, and nurture innovation.
Responsibilities
  • Continuously improve operational and reporting processes for national prescription and sales data in support of cross-functional business teams, including APEX Analytics, Forecasting, and Business Development.
  • Lead the Immunology repositories process, including interfacing with national data suppliers to understand changes in data capture, communicating changes to national data users, and implementing Immunology business-rule changes under APEX Immunology leadership guidance.
  • Assist in supervising the offshore team supporting repositories.
  • Coordinate cross-functional data enablement, validation, and operational readiness for NPCL/CDLM, the US Commercial KPI Tracker, ELT Trackers, and related automation initiatives across therapeutic areas.
  • Act as Data Steward for syndicated national data, ensuring adherence to the USTO Data Governance Operating Model and overseeing and improving the offshore support team's data quality management activities.
  • Identify relevant changes in data capture through supplier interfaces and partner with Immunology APEX leadership to implement appropriate corrections; champion data governance improvements aligned with Commercial Data Operations leadership.
  • Manage the business data glossary and ensure terms, classifications, and business rules are documented and accessible to data users.
  • Ensure compliance-related classifications and tagging are complete for all Critical Data Elements.
  • Define, document, map, and validate standard and custom data quality checks; coordinate onboarding of results into CDQM and the Central DQ Dashboard; track ownership, resourcing, approval, and timeline dependencies through completion.
  • Assist the Manager, National Reporting with weekly and monthly KPI tracking and executive performance reporting.
  • Ensure smooth operations and continuous improvement of internal and third-party analytics pipelines.
  • Manage interactions with external national-data vendors.
  • Lead and interact with the offshore team supporting reporting and repositories, aligned with the National Reporting Manager, and serve as subject matter expert for Immunology repositories.
  • Lead user acceptance testing and source-to-output validation for new metrics and repository enhancements; document test evidence, investigate discrepancies, distinguish confirmed issues from items pending clarification, and coordinate business sign-off before production deployment.
  • Assist the Manager in coordinating LBE, PLAN, and actuals inputs with Finance, brand analytics, and reporting teams; confirm source-file completeness, reporting periods, metric definitions, and delivery timing; communicate interim approaches when required inputs are delayed or incomplete.
  • Maintain the enterprise report registry and supporting SharePoint inventory across therapeutic areas; validate report lifecycle information, identify duplicate or discontinued outputs, and support recommendations for continuation, consolidation, automation, or retirement.
  • Establish cross-functional relationships with APEX Analytics, Immunology, Data Governance, Data Strategy, and Forecasting teams.
  • Assist with communicating data changes and enhancements implemented at vendor partners to senior executives and APEX analytics teams.
  • Coordinate end-to-end workstreams across APEX, Data Governance, BTS, Finance, brand teams, and external partners by documenting decisions, owners, deliverables, dependencies, target dates, and required approvals; escalate risks that could affect production deployment or reporting timelines.
Desired Qualifications
  • An MBA or master's degree in computer science, data science, or a related technical field is preferred.
  • Experience with Python is a plus.
  • A deep understanding of the pharmaceutical commercial environment and business needs is preferred.
  • Experience communicating to leadership in a large multinational organization, with appropriate alignment to the reporting line and attention to detail in executive-ready communications, is a plus.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 24th, 2026
AbbVie wins FDA nod for at-home Skyrizi starts in Crohn's; sales boost seen after 60-90 days

AbbVie won US Food and Drug Administration (FDA) approval on October 23 for an at-home start to Skyrizi in adults with moderately to severely active Crohn's disease. Patients previously had to begin with intravenous infusions; they can now take the first doses at home with an on-body injector. By Week 12, 74% of patients new to advanced therapy reached clinical remission, against 27% on placebo. Johnson & Johnson's rival Tremfya won similar approval about 19 months earlier. Chief commercial officer Jeff Stewart said full paid access "will probably take 60 or 90 days" because insurers must approve the regimen. Sales impact should therefore come mostly after the fourth quarter. AbbVie reports third-quarter results on October 30. It guides for revenue of about $17.2 billion; Skyrizi's franchise sold $17.562 billion in 2025.

Yahoo Finance
Oct 23rd, 2026
ETFs net sell $42.1M of AbbVie as XLV leads $32.0M exit

Exchange-traded funds (ETFs) were net sellers of AbbVie shares for a second straight session, selling a net $42.1 million on October 21. Sellers moved larger sums even though more funds bought than sold: 24 ETFs added shares and 23 cut them. The Health Care Select Sector SPDR Fund led the selling with $32.0 million, followed by iShares Core S&P 500 ETF at $9.3 million and SPDR S&P 500 ETF Trust at $2.0 million. On October 20, ETFs sold a net $6.7 million, after three days of net buying. AbbVie has a market cap of $504.0 billion. Trailing 12-month revenue was $64.39 billion, up 10.3% over the past year.

Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.